A couple of recent reviews in Atherosclerosis journal on epigenetic processes and epigenetic drugs as they relate to cardiometabolic disease and atherosclerosis. I didn't see them listed on PubMed yet, but I found them on the Atherosclerosis journal page in the Articles in Press section while looking at the HDL/T2D article I posted about previously. Both give apabetalone some love.

Epigenetic processing in cardiometabolic disease

Potential epigenetic therapeutics for atherosclerosis treatment